The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 39.00
Bid: 38.50
Ask: 39.50
Change: 0.00 (0.00%)
Spread: 1.00 (2.597%)
Open: 39.00
High: 38.70
Low: 38.70
Prev. Close: 39.00
VLG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

30-year exclusive distribution deal signed

26 Jan 2015 07:00

RNS Number : 0861D
Venture Life Group PLC
26 January 2015
 



26 January 2015

 

Venture Life Group plc

 

("Venture Life" or "the Group")

 

30-year exclusive distribution deal with major skincare and cosmetics retailer in China

 

Venture Life Group plc (AIM: VLG), the international consumer products group addressing the self-care needs of the ageing population, announces that it has signed an exclusive 30-year distribution deal with one of the largest skincare and cosmetics retail chains in China.

 

The agreement is with REC Cosmetics (Shanghai) Limited ("REC"), a subsidiary of Gialen Group Co. Ltd ("Gialen"). Gialen is a privately owned business with 10,000 employees operating in over 1,000 of its own retail skincare and cosmetics stores across mainland China. Gialen is currently undertaking a rapid new store opening programme and over 300,000 customers currently visit their stores daily.

 

Under the terms of the distribution agreement, REC has the exclusive right to sell an initial range of 15 skincare products, including some products from Venture Life's anti-ageing range, ("the Initial Range") in China, Macau, Hong Kong and Taiwan. Venture Life will be the exclusive manufacturer and supplier to REC for all current and any future products under the agreement.

 

The Initial Range is expected to be launched in Gialen Group stores in China in the second half of 2015, subject to registration approval. For the Initial Range, contractual annual minimum purchase obligations ("MPO") have been agreed, the achievement of which maintains REC's rights to distribute the products. The MPO are worth approximately RMB 52.8m (£5.7m)* in sales for Venture Life over the first five years after product registration, including RMB 8.5m (£0.9m)* during the first year after registration. Over the full term of the agreement, the total MPO are worth approximately RMB 371m/£40m* in sales for Venture Life.

 

Jerry Randall, Chief Executive Officer of Venture Life, commented:

 

"We are delighted to have signed a very significant deal with such a progressive, fast-growing Chinese skincare and cosmetics business. We have worked through a very detailed process to arrive at this agreement with a partner who clearly shares our philosophy, ethos and ambition to grow in China.

 

"This agreement demonstrates there is a strong appetite for our products in China and the other territories, where the demand for high quality Western products, particularly in skincare, remains strong. Our Italian manufacturing capacity and capability has also been a major factor in securing this agreement, and further validates our strategic approach as an integrated product development, manufacturing and commercialisation company. We expect this deal to represent just the start of a very successful collaboration with Gialen in China."

 

* At current exchange rates as the Initial Range is priced in RMB.

- Ends -

 

For further information please contact:

Venture Life Group PLC

Jerry Randall, Chief Executive Officer

James Hunter, Chief Financial Officer +44 (0) 1344 742 870

 

Panmure Gordon (UK) Limited Freddy Crossley / Duncan Monteith +44 (0) 20 7886 2500Corporate Finance

Tom SalvesenCorporate Broking

 

Square1 Consulting

David Bick

Mark Longson +44 (0) 20 7929 5599

 

Notes to editors

 

About Venture Life

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product range and pipeline currently include food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medical devices for improving minor aches and pains, dry eyes and itchy skin. The products, which typically are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.

 

Through its manufacturing company, Biokosmes, the Group also provides development and manufacturing services to companies in the medical device and cosmetic sectors.

The Group's own branded products are currently sold or partnered in over 40 countries and currently include:

· food supplements to maintain brain function and memory;

· dermo-cosmetics for addressing the signs of skin ageing and hair loss, and

· medical devices for improving conditions such as minor aches and pains, dry eyes and itchy skin.

 

The Company has a healthy development pipeline including products in areas such as diabetes, cardiovascular health, obesity, cognitive function and skin ageing. Products coming from the pipeline will be expected to have intellectual property protection and be supported by independent clinical evidence of efficacy.

 

About Gialen

Gialen was founded in 2005 and is headquartered in Guangzhou, China. Gialen is one of the largest cosmetics retail chains in China with over 1,000 stores and 300,000 customers daily.

 

Gialen sells an extensive range of products, listing some of the world's best known skincare, cosmetics and personal-care brands including L'Oreal, Shiseido, Olay and Nivea.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRBAMBTMBMTTAA
Date   Source Headline
8th Jan 20187:00 amRNSEuropean Business Awards 'Ones to Watch List'
24th Nov 20177:00 amRNSNew exclusive partner secured in Austrian market
23rd Nov 201711:14 amRNSUK Bond Network presentation
14th Nov 20177:00 amRNSVox Markets
30th Oct 20177:00 amRNSUltraDEX update
10th Oct 20177:00 amRNSHolding(s) in Company
2nd Oct 20177:00 amRNSFDA approval for the US market
21st Sep 20177:00 amRNSHalf-year Report
7th Sep 20177:00 amRNSDistribution partners and Lubatti China update
4th Sep 20177:00 amRNSNotice of Results
7th Aug 20174:24 pmRNSDirector/PDMR Shareholding
19th Jul 20177:00 amRNSDistribution partner for UltraDEX & patent update
12th Jul 20177:00 amRNSTrading update
23rd May 201710:59 amRNSResult of AGM
23rd May 20177:00 amRNSUltraDEX Patent Grants and Distribution Update
18th May 20177:00 amRNSTwo new CE Mark approvals
10th May 20179:00 amRNS'1000 Companies to Inspire Britain' 2017 report
4th May 20177:00 amRNSChange of Adviser
4th May 20177:00 amRNSGrant of Options
25th Apr 20177:00 amRNS2017 Long Term Incentive Plan and Grant of Options
29th Mar 20173:36 pmRNSUK Investor Show attendance
23rd Mar 20177:00 amRNSFinal Results
1st Mar 20177:00 amRNSDirectorate Change
1st Feb 20171:08 pmRNSHolding(s) in Company
31st Jan 20174:39 pmRNSInvestor Day presentation now available
26th Jan 20177:00 amRNSTrading update
20th Dec 20167:00 amRNSInvestor evening
29th Nov 20166:06 pmRNSHolding(s) in Company
28th Nov 20167:00 amRNSAppointment of Vox Markets
17th Nov 20167:00 amRNSInvestor evening
14th Nov 20167:00 amRNSTrading update
10th Nov 20167:00 amRNSDirectorate Change
10th Oct 20167:00 amRNSUltraDEX advertising launch
7th Oct 201612:10 pmRNSIssue of Equity
29th Sep 20167:00 amRNS2016 LTIP adopted & Grant of Options
21st Sep 20167:00 amRNSHalf-year Report
21st Sep 20167:00 amRNSAppointment of joint broker
7th Sep 20167:00 amRNSNotice of Results
29th Jul 20167:00 amRNSPre-close trading statement
22nd Jun 201612:35 pmRNSResult of AGM
14th Jun 201612:18 pmRNSDirector/PDMR Shareholding
17th May 20164:17 pmRNSDirector/PDMR Shareholding
9th May 20161:13 pmRNSDirector/PDMR Shareholding
9th May 20167:00 amRNSAnnual Financial Report
4th May 20167:00 amRNSFinal Results
3rd May 20167:00 amRNSFirst distribution agreements signed for UltraDEX
31st Mar 20167:00 amRNSDistribution Deals on Benecol 'once a day' Sachet
29th Mar 20167:02 amRNSNotice of Results
18th Mar 201611:04 amRNS'1000 Companies to Inspire Britain 2016' report
7th Mar 20167:00 amRNSCompletion of Acquisition

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.